SRR934741
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 36.826544021024965
- age_years
- 46
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.605
- IL6_JAK_STAT3_SIGNALING+0.602
- INTERFERON_GAMMA_RESPONSE+0.601
- ALLOGRAFT_REJECTION+0.557
- INFLAMMATORY_RESPONSE+0.556
- INTERFERON_ALPHA_RESPONSE+0.552
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.496
- TGF_BETA_SIGNALING+0.494
- IL2_STAT5_SIGNALING+0.479
- ANGIOGENESIS+0.457
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.376
- KRAS_SIGNALING_DN-0.303
- OXIDATIVE_PHOSPHORYLATION-0.280
- HEDGEHOG_SIGNALING-0.240
- MYC_TARGETS_V2-0.159
- MYOGENESIS-0.103
- WNT_BETA_CATENIN_SIGNALING-0.072
- MYC_TARGETS_V1-0.060
- FATTY_ACID_METABOLISM-0.035
- PEROXISOME-0.002
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934862 | — | — | 0.931 |
| 2 | 7E4D42B3-FD9B-4184-A4A0-E52E45259428 | — | — | 0.929 |
| 3 | 738B9C39-A73F-4BD5-A8D4-3F75B9E14569 | — | — | 0.924 |
| 4 | TCGA-DK-A2I4-01A-11R-A21D-07 | — | — | 0.921 |
| 5 | SRR934811 | — | — | 0.920 |
| 6 | SRR934901 | — | — | 0.919 |
| 7 | BS_9HA238XS | Neurofibroma | — | 0.914 |
| 8 | MDT-AP-3264 | Med | Medulloblastoma | 0.912 |
| 9 | SRR934908 | — | — | 0.910 |
| 10 | BS_D5P6EZ1M | Schwannoma | — | 0.908 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.605 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.602 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.601 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.557 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.556 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.552 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.496 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.494 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.479 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.457 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.449 | Inavolisib | — uncovered |
| APOPTOSIS | 0.432 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.428 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.404 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.367 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.284 | Inavolisib | — uncovered |
| COAGULATION | 0.275 | Binimetinib | — uncovered |
| NOTCH_SIGNALING | 0.267 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.264 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.244 | Inavolisib | — uncovered |